跳至主要内容
临床试验/TCTR20190602002
TCTR20190602002已完成未知

Clinical Outcomes and Prognostic Factors to Predict Treatment Response in High Risk Neuroblastoma Patients Receiving Topotecan and Cyclophosphamide Containing Induction Regimen: A Prospective Multicenter Study

Phramongkutklao Hospital and College of Medicine0 个研究点目标入组 107 人开始时间: 2019年6月2日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
107

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
0 Years 至 18 Years(—)
性别
All

入选标准

  • The study’s inclusion criteria include patients less than 18 years of age who had a new diagnosis of high risk neuroblastoma stratified as per the International Neuroblastoma Risk Group Staging System (INRGSS).

排除标准

  • Patients contra-indicated for topotecan or receiving a diagnosis of refractory or relapsed neuroblastoma

研究者

发起方
Phramongkutklao Hospital and College of Medicine

相似试验